The EPOS trial: effective patient-clinician communication in community mental health care

Conditions

Schizophrenia Mental and Behavioural Disorders Schizophrenia

Stefan Priebe, Eoin Golden, David Kingdon, Serif Omer, Sophie Walsh et al. (9 authors)

Programme Grants for Applied Research2017-02-0134 citations

Exploring the Mechanisms of a Patient-Centred Assessment with a Solution Focused Approach (DIALOG+) in the Community Treatment of Patients with Psychosis: A Process Evaluation within a Cluster-Randomised Controlled Trial

Serif Omer, Eoin Golden, Stefan Priebe

PLoS ONE2016-02-0951 citations

10.1371/journal.pone.0148415

Effectiveness of structured patient-clinician communication with a solution focused approach (DIALOG+) in community treatment of patients with psychosis--a cluster randomised controlled trial.

Priebe S, Kelley L, Golden E, McCrone P, Kingdon D, Rutterford C, McCabe R.

2013-06-2631 citations

10.1186/1471-244x-13-173

Interventions

DIALOG Scale: The control group will include treatment as usual plus a defined intervention that also involves the use of an Apple iPad and an assessment of the patient's satisfaction. The patient wil

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients: 1. Treatment in a community mental health care team in the NHS for at least one month 2. Clinical diagnosis of schizophrenia or a related disorder (F20-29) 3. Aged between 18 and 65 years 4. A mean score of less than 5 on the Short Assessment of Quality of Life (MANSA) 5. Capacity to give informed consent Key workers: 1. Professional qualification as a clinician (nurse, social worker, psychologist, occupational therapist, doctor) 2. More than 6 months experience of working in community mental health care 3. Working as care coordinator

Exclusion criteria

Exclusion criteria: Patients: 1. Insufficient command of the English language for conducting meetings in English and filling in the assessment instruments of outcomes 2. A mean score of 5 or more on the MANSA 3. Learning difficulties Key workers: None

Design outcomes

Primary

Measure	Time frame
Subjective quality of life measured on the Manchester Short Assessment of Quality of Life (MANSA) Assessed at baseline, and at months 3, 6 and 12	—

Secondary

Measure	Time frame
1. Costs of formal and informal care, assessed on the Client Service Receipt Inventory (CSRI) 2. Mental well-being on the Warwick-Edinburgh Mental Well-Being Scale (WEMWBS) 3. Needs on the Camberwell Assessment of Need Short Appraisal Schedule, patient-rated version (CANSAS) 4. Objective Social Outcomes measured on the SIX scale, also assessed using the MANSA (sections 2a and 3) 5. Psychopathological Symptoms on the Brief Psychiatric Rating Scale (BPRS) 6. Recovery as measured on the severity parts of each of the 24 items of the CHOICE scale 7. Self-Efficacy on the General Self-Efficacy Scale 8. Social contacts in the last week measured in a structured interview 9. The Therapeutic Relationship measured on the Scale to Assess Therapeutic Relationships in Community Mental Health Care (STAR) patient and clinician versions All secondary outcome measures will be assessed at baseline, and at months 3, 6 and 12	—

Measure

Time frame

1. Costs of formal and informal care, assessed on the Client Service Receipt Inventory (CSRI) 2. Mental well-being on the Warwick-Edinburgh Mental Well-Being Scale (WEMWBS) 3. Needs on the Camberwell Assessment of Need Short Appraisal Schedule, patient-rated version (CANSAS) 4. Objective Social Outcomes measured on the SIX scale, also assessed using the MANSA (sections 2a and 3) 5. Psychopathological Symptoms on the Brief Psychiatric Rating Scale (BPRS) 6. Recovery as measured on the severity parts of each of the 24 items of the CHOICE scale 7. Self-Efficacy on the General Self-Efficacy Scale 8. Social contacts in the last week measured in a structured interview 9. The Therapeutic Relationship measured on the Scale to Assess Therapeutic Relationships in Community Mental Health Care (STAR) patient and clinician versions All secondary outcome measures will be assessed at baseline, and at months 3, 6 and 12

—

Countries

United Kingdom

Outcome results

None listed